Clinical Implication of Cystatin C and β-Microglobulin in Early Detection of Diabetic Nephropathy

被引:32
作者
Chen, Hongmei [1 ]
Li, Hongbin [1 ]
机构
[1] Second Peoples Hosp Nantong, Dept Endocrinol, 43 Xinglong St, Nantong 226002, Peoples R China
关键词
cystatin C; beta; 2-microglobulin; diabetic nephropathy; early detection; type 2 diabetes mellitus; SERUM CREATININE; RENAL-DISEASE; MELLITUS; STAGE; COMPLICATIONS; DIAGNOSIS; EXCRETION; GLUCOSE;
D O I
10.7754/Clin.Lab.2016.160719
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Diabetic nephropathy (DN) is one of the major late complications of type 2 diabetes mellitus (T2DM). The aim of this study was to evaluate the efficiency of cystatin C (cysC) and beta 2-microglobulin ((beta 2 -MG) in diagnosing early DN and to identify the optimal threshold in the Chinese patients. Methods: T2DM patients were divided into 102 non-DN subjects, 60 early DN subjects, and 38 clinical DN subjects. Blood and urine measurements were compared among the groups. Receiver-operating characteristic (ROC) curves and areas under the curve (AUC) were calculated to demonstrate the prediction values of the variables. Results: Stepwise regression analysis showed that the levels of cysC and 132 -MG were associated with early DN. The AUC was 0.874 for cysC and 0.792 for beta 2-MG. The threshold based on the ROC curve had the best diagnostic performance compared with the threshold with respect to mean + SD (standard deviation) and parallel tests. A high sensitivity of 91.67% was achieved at the cysC threshold of 0.91 mg/L with a moderate specificity of 76.47% and a sensitivity of 80.00% for the beta 2-MG threshold of 1.86 mg/L with a specificity of 67.65%. Conclusions: The findings suggest that the cysC threshold of 0.91 mg/L may be acceptable as a diagnostic criterion for early DN in the Chinese patients. The results also suggest that for T2DM patients the normal reference range of cysC should be set lower in favor of early DN screening.
引用
收藏
页码:241 / 247
页数:7
相关论文
共 25 条
[1]   β2-microglobulin and cystatin C in type 2 diabetes:: Assessment of diabetic nephropathy [J].
Aksun, SA ;
Özmen, D ;
Özmen, B ;
Parildar, Z ;
Mutaf, I ;
Turgan, N ;
Habif, S ;
Kumanliogluc, K ;
Bayindir, O .
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2004, 112 (04) :195-200
[2]  
Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO
[3]  
2-S
[4]  
ANDERSEN AR, 1983, DIABETOLOGIA, V25, P496
[5]   INCREASED INCIDENCE OF END-STAGE RENAL-FAILURE SECONDARY TO DIABETES-MELLITUS IN ASIAN ETHNIC-GROUPS IN THE UNITED-KINGDOM [J].
BURDEN, AC ;
MCNALLY, PG ;
FEEHALLY, J ;
WALLS, J .
DIABETIC MEDICINE, 1992, 9 (07) :641-645
[6]   The need for early predictors of diabetic nephropathy risk - Is albumin excretion rate sufficient? [J].
Caramori, ML ;
Fioretto, P ;
Mauer, M .
DIABETES, 2000, 49 (09) :1399-1408
[7]   Genetic determinants of diabetic nephropathy [J].
Chowdhury, TA ;
Dyer, PH ;
Kumar, S ;
Barnett, AH ;
Bain, SC .
CLINICAL SCIENCE, 1999, 96 (03) :221-230
[8]   Adult cystatin C reference intervals determined by nephelometric immunoassay [J].
Croda-Todd, Maria Teresa ;
Soto-Montano, Xavier J. ;
Hernandez-Cancino, Pedro A. ;
Juarez-Aguilar, Enrique .
CLINICAL BIOCHEMISTRY, 2007, 40 (13-14) :1084-1087
[9]   Serum cystatin C is superior to serum creatinine as a marker of kidney function: A meta-analysis [J].
Dharnidharka, VR ;
Kwon, C ;
Stevens, G .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2002, 40 (02) :221-226
[10]  
Feriozzi S, 2007, J NEPHROL, V20, P437